Published in Antimicrob Agents Chemother on March 01, 1976
Pharmacology of cinoxacin in humans. Antimicrob Agents Chemother (1979) 1.05
Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function. Antimicrob Agents Chemother (1979) 0.75
In vitro activity of cinoxacin, ampicillin, and chloramphenicol against Shigella and nontyphoid Salmonella. Antimicrob Agents Chemother (1977) 0.75
Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother (1975) 5.49
Compound 64716, a new synthetic antibacterial agent. Antimicrob Agents Chemother (1973) 4.11
Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med (1974) 2.05
Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother (1975) 1.50
Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother (1996) 4.41
Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis (1973) 3.67
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother (2009) 3.62
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother (1979) 3.49
Pharmacology of gentamicin in man. J Infect Dis (1971) 3.16
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect (2010) 2.63
Current therapeutics. 234. Gentamicin. Practitioner (1967) 2.54
Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med (1972) 2.19
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill (2008) 2.13
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis (1972) 2.06
Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis (1971) 1.97
Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis (1971) 1.89
An evaluation of the use of statistical methodology in the Journal of Infectious Diseases. J Infect Dis (1984) 1.82
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother (2001) 1.74
Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother (1988) 1.70
Viremia in Asian influenza. Trans Assoc Am Physicians (1966) 1.70
Central nervous system manifestations of Mycoplasma pneumoniae infections. J Infect (2005) 1.65
Humoral and cellular response in humans after immunization with influenza vaccine. Infect Immun (1973) 1.54
Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother (1975) 1.50
Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. Antimicrob Agents Chemother (1972) 1.48
Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1979) 1.47
Acute respiratory illness among immunized and nonimmunized patients with high-risk factors during a split season of influenza A and B. J Infect Dis (1988) 1.46
Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol (1968) 1.42
Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis (2001) 1.42
First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother (1991) 1.40
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med (1986) 1.38
Classification of oral cephalosporins. A matter for debate. Int J Antimicrob Agents (2001) 1.38
Observations of the staphylococcal nasal carrier state. Ann N Y Acad Sci (1965) 1.34
First identification of an Escherichia coli clinical isolate producing both metallo-beta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1. Clin Microbiol Infect (2004) 1.34
Production of interferon in volunteers infected with Asian influenza. J Infect Dis (1970) 1.33
Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA (1975) 1.31
Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection (1994) 1.31
Netilmicin: clinical efficacy, tolerance, and toxicity. Antimicrob Agents Chemother (1978) 1.29
Prevention of illness from rhinovirus infection by a topical interferon inducer. N Engl J Med (1974) 1.27
Dispensing of antibiotics without prescription in Greece, 2008: another link in the antibiotic resistance chain. Euro Surveill (2010) 1.27
High-pressure liquid chromatographic assay of netilmicin in plasma. Antimicrob Agents Chemother (1977) 1.21
Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses. J Infect Dis (1973) 1.17
Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A. Am Rev Respir Dis (1976) 1.15
Effect of antibiotic prophylaxis in percutaneous endoscopic gastrostomy. Am J Gastroenterol (1985) 1.15
Viremia with herpes simplex type 1 in adults. Four nonfatal cases, one with features of chicken pox. Ann Intern Med (1976) 1.15
Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect (2013) 1.14
Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis (1977) 1.14
Pentoxifylline in the treatment of experimental peritonitis in rats. Arch Surg (1985) 1.14
Hemorrhage, diarrhea, and superinfection associated with the use of moxalactam. J Infect Dis (1983) 1.13
Antiviral agents in influenza--summary of Influenza Workshop VIII. J Infect Dis (1976) 1.12
Attitudes and behavior of health care personnel regarding the use and efficacy of influenza vaccine. J Infect Dis (1985) 1.10
Detection of aac(6')-I genes in amikacin-resistant Acinetobacter spp. by PCR. Antimicrob Agents Chemother (1994) 1.10
Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect (2011) 1.08
Viruses causing common respiratory infections in man. J Infect Dis (1973) 1.08
Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection (2010) 1.06
In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 1.06
The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J Infect Dis (1973) 1.05
Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother (1997) 1.05
Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J Infect Dis (1986) 1.04
Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol (2006) 1.04
Influence of population density on antibiotic resistance. J Antimicrob Chemother (2003) 1.04
Use of intravenous ciprofloxacin in difficult-to-treat infections. Am J Med (1987) 1.04
Effects of slime produced by clinical isolates of coagulase-negative staphylococci on activities of various antimicrobial agents. Antimicrob Agents Chemother (1998) 1.04
Nosocomial Mycobacterium gordonae pseudoinfection from contaminated ice machines. Infect Control (1986) 1.03
Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol (2007) 1.02
Prevention and control of influenza by chemoprophylaxis and chemotherapy. Prospects from examination of recent experience. JAMA (1976) 1.02
Methods for the clinical evaluation of antibiotics in urinary tract infections. Scand J Infect Dis Suppl (1978) 1.02
Herpes virus latency in spinal ganglia of mice without illness. Proc Soc Exp Biol Med (1974) 1.00
Nosocomial vs. community-acquired infective endocarditis in Greece: changing epidemiological profile and mortality risk. Clin Microbiol Infect (2007) 1.00
In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother (1989) 0.99
Protection with split and whole virus vaccines against influenza. Arch Intern Med (1973) 0.99
Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol (1986) 0.99
Prevalence of 16S rRNA methylase genes in Enterobacteriaceae isolates from a Greek university hospital. Clin Microbiol Infect (2012) 0.99
Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis (1988) 0.98
Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis (1984) 0.98
Treatment with metronidazole of 48 patients with serious anaerobic infections. J Antimicrob Chemother (1977) 0.98
Cefuroxime: antimicrobial activity, human pharmacokinetics and therapeutic efficacy. J Antimicrob Chemother (1977) 0.98
Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 0.97
Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol (2005) 0.97
An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol (2007) 0.97
Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother (1982) 0.97
Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clin Exp Immunol (2004) 0.97
Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections. Eur J Clin Microbiol (1983) 0.97
Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus. J Antimicrob Chemother (1989) 0.97
Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother (1995) 0.96
Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (1997) 0.95
Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of resistance and serotype epidemiology. Int J Antimicrob Agents (2007) 0.95
Antibody-coated bacteria in urine: when, where and why? J Antimicrob Chemother (1984) 0.95
Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis (2001) 0.94
Study of delayed hypersensitivity to myxoviruses induced by vaccines. Appl Microbiol (1969) 0.94
In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother (2003) 0.93
The effect of heparin upon fibrinopurulent peritonitis in rats. Surg Gynecol Obstet (1983) 0.92
Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up. Antimicrob Agents Chemother (1984) 0.91
Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA (1985) 0.91
'Methicillin resistant' Staphylococcus aureus infections during 1978-79: clinical and bacteriologic observations. J Antimicrob Chemother (1981) 0.91
Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency. Chemotherapy (1981) 0.91
Nasal-secretion leukocyte populations determined by flow cytometry during acute rhinovirus infection. J Med Virol (1988) 0.91
Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis. J Infect Dis (1982) 0.91
Infecton: a 99mTc-ciprofloxacin radiopharmaceutical for the detection of bone infection. Clin Microbiol Infect (2003) 0.91
Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect (2007) 0.91